公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 股票简称：华海药业 股票代码：600521 公告编号：临 2025-066 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 会议召开时间：2025 年 06 月 03 日（星期二）15:00-16:00； 会议召开地点：上海证券交易所上证路演中心（网址： 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 06 月 03 日 （星期二） 15:00-16:00； 重要内容提示： https://roadshow.sseinfo.com/）； 会议召开方式：上证路演中心视频录播和网络互动； 投资者可于 2025 年 05 月 26 日（星期一）至 05 月 30 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江华海药业股份有限 ...

Group 1 - The company held an investor reception day on May 23, 2025, to enhance governance and investor relations, with participation from management and 55 investors [1][9] - Key management personnel, including the CFO and Vice Presidents, presented on business operations, development strategies, and governance [1][2] Group 2 - The subsidiary Shanghai Huaotai Biopharmaceutical Co., Ltd. is focused on innovative drug development, particularly in oncology and autoimmune diseases, with a mature pipeline of large molecule antibody drugs [1][2] - The HB0034 project for treating generalized pustular psoriasis has completed key clinical trials and is preparing for NDA submission, expected to be approved next year [2] - The HB0017 project for psoriasis has completed patient enrollment for Phase III trials, showing positive treatment effects [2] - The company is advancing several other projects, including HB0043 and HB0056, which are set to enter clinical trials soon [2][4] Group 3 - The company is closely monitoring the impact of US-China tariffs, which are currently limited, and is focused on enhancing core competitiveness [4] - Fixed asset investments are primarily directed towards biopharmaceutical production bases, with several nearing completion and expected to support steady growth as new products are approved [4][5] Group 4 - The company aims to achieve a sales revenue target of 10.5 billion yuan by 2025, focusing on core strategies and enhancing operational efficiency [5][6] - The strategy includes a comprehensive approach to product development, emphasizing high-end complex generics and innovative drugs, while maintaining a robust product pipeline [6] Group 5 - The company is experiencing competitive pressure in the market for sartans, with prices remaining low due to supply-demand dynamics [7][8] - The domestic formulation business is driven by innovation, with a focus on expanding into new therapeutic areas and enhancing market coverage [8] Group 6 - The company is implementing measures to address price pressures from domestic centralized procurement policies, including cost control and market management strategies [8]

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-065 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 关于公司投资者接待日活动举办情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步提高公司治理水平，加强投资者关系管理，增进公司与广大投资者 的沟通和交流，浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日举办了投资者接待日活动，公司管理层就公司经营情况、发展战略、公 司治理等投资者关心的问题与广大投资者进行了现场的沟通和交流。具体情况如 下： 一、投资者接待日基本情况 1、活动时间：2025 年 5 月 23 日（周五）9:30—12:30； 2、活动地点：浙江省临海市汛桥浙江华海药业股份有限公司； 3、活动召开方式：现场召开 4、参加活动的人员：公司董事兼总裁陈保华先生，公司董事、副总裁兼董 事会秘书祝永华先生，公司高 ...

| 股票简称：华海药业 | 股票代码：600521 公告编号：临 | 2025-062 号 | | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | 浙江华海药业股份有限公司 关于下属子公司获得药物临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）的下属 子公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）获得新西兰药品和 医疗器械安全管理局（以下简称"MEDSAFE"）、健康及残疾伦理委员会（以下简称 "HDEC"）批准，在当地开展注射用 HB0043 I 期临床试验。现将相关情况公告如下： 一、药物基本情况 药物名称：注射用 HB0043 适应症：自身免疫疾病 申请事项：临床试验 申请人：上海华奥泰生物药业股份有限公司 结论：同意开展临床试验 二、药物的其他相关情况 请广大投资者理性投资，注意投资风险。 特此公告。 浙江华海药业股份有限公司 2025年4月，公司下属子公司华奥泰向MED ...

证券代码：600521 证券简称：华海药业 公告编号：临 2025-063 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 23 日 (二)股东大会召开的地点：浙江省临海市汛桥镇浙江华海药业股份有限公司会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 670 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 564,612,748 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 37.8877 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 1 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票 ...

浙江天册律师事务所 关于 浙江华海药业股份有限公司 2024 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江华海药业股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0659 号 致：浙江华海药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江华海药业股份有限公司（以 下简称"华海药业"或"公司"）的委托，指派本所律师参加公司 2024 年年度股 东大会，并根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）和《上市公司股东会规则》（以 下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求及《浙江 华海药业股份有限公司章程》（下称"《公司章程》"）《浙江华海药业股份有限公 司股东大会议事规则》（下称"《议事规则》"）的规定出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及 ...

| 证券简称：华海药业 | 证券代码：600521 | 公告编号：临 2025-064 号 | | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | 浙江华海药业股份有限公司 第九届董事会第一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第一次临时会 议于二零二五年五月二十三日在公司四楼会议室以现场方式召开。会议应到会董 事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 李宏先生主持，公司高级管理人员列席了会议。会议程序符合《中华人民共和国 公司法》（以下简称"公司法"）及《浙江华海药业股份有限公司公司章程》（以 下简称"公司章程"）的规定，会议合法有效。会议审议并通过了如下决议： 一、审议通过了《关于选举公司董事长的议案》； 表决情况：同意：9 票；反对：0 票；弃权：0 票。 会议决议：选举李宏先生为公司董事长，任期至第九届董事会届满。 二、审议通过了《关于聘任公司总裁的议案 ...

| 300705 | 九典制 | 0.44 | 3.37 | 660.10 | 3.35 | | --- | --- | --- | --- | --- | --- | | | 药 | | | | | | 600572 | 康恩贝 | 0.68 | 1.45 | 627.79 | 3.76 | | 002349 | 精华制 | 0.81 | 2.27 | 571.95 | 4.13 | | | 药 | | | | | | 002004 | 华邦健 | 0.25 | 0.80 | 571.40 | 9.29 | | | 康 | | | | | | 688553 | 汇宇制 | 1.93 | 1.88 | 555.55 | 5.80 | | | 药 | | | | | | 300086 | 康芝药 | -0.39 | 3.88 | 517.25 | 5.87 | | | 业 | | | | | | 002907 | 华森制 | 3.77 | 5.14 | 493.67 | 2.10 | | | 药 | | | | | | 000908 | *ST景峰 | 1.19 | 2.66 | 475.12 | 3.98 | ...

Group 1 - The cell immunotherapy concept index rose by 1.35%, ranking third among concept sectors, with 35 stocks increasing in value, including Seer Medical which hit the daily limit, and Sunshine Nuohuo, Shutai Shen, and Betta Pharmaceuticals showing significant gains of 12.55%, 11.77%, and 8.35% respectively [1] - The concept sector saw a net inflow of 246 million yuan, with 29 stocks receiving net inflows, and 5 stocks attracting over 50 million yuan in net inflows, led by Huahai Pharmaceutical with a net inflow of 143 million yuan [1] - The top stocks by net inflow included Seer Medical, Huadong Medicine, and Saifutian, with net inflows of 126 million yuan, 106 million yuan, and 74 million yuan respectively [1] Group 2 - The leading stocks by net inflow ratio were Saifutian, Seer Medical, and Hai Xin Co., with net inflow ratios of 20.66%, 18.75%, and 15.23% respectively [2] - Huahai Pharmaceutical had a daily increase of 7.45% with a turnover rate of 7.28%, while Seer Medical increased by 10.04% with a turnover rate of 30.03% [2] - Other notable stocks included Betta Pharmaceuticals with an 8.35% increase and a turnover rate of 5.70%, and Rongchang Bio with a 2.08% increase and a turnover rate of 4.97% [2] Group 3 - Stocks with significant declines included Yaoji Technology, Hainan Hai Pharmaceutical, and Nearshore Protein, which fell by 4.24%, 3.62%, and 3.19% respectively [1] - The overall performance of the cell immunotherapy sector reflects a positive trend, with a majority of stocks experiencing gains, indicating investor confidence in this area [1][2] - The data suggests a strong interest from institutional investors in the cell immunotherapy sector, as evidenced by the substantial net inflows into key stocks [1][2]

Group 1 - The innovative drug concept index rose by 0.97%, ranking 7th among concept sectors, with 116 stocks increasing in value [1] - Notable gainers included Hai Chen Pharmaceutical, which hit the daily limit with a 20% increase, and other companies like Xian Da Co., Zhong Sheng Pharmaceutical, and Hai Xiang Pharmaceutical also reached their daily limits [1] - The top gainers in the sector were Yang Guang Nuo He, Shu Tai Shen, and Bei Da Pharmaceutical, with increases of 12.55%, 11.77%, and 8.35% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 438 million yuan, with 81 stocks receiving net inflows, and 5 stocks exceeding 100 million yuan in net inflows [2] - Hai Chen Pharmaceutical led the net inflow with 179 million yuan, followed by Zhong Sheng Pharmaceutical, Hua Hai Pharmaceutical, and Xian Da Co. with net inflows of 177 million yuan, 143 million yuan, and 110 million yuan respectively [2][3] - The net inflow ratios for Zhong Sheng Pharmaceutical, Xian Da Co., and Hai Chen Pharmaceutical were 42.93%, 17.67%, and 15.92% respectively [3] Group 3 - The innovative drug sector's performance was highlighted by the significant trading volume and turnover rates, with Hai Chen Pharmaceutical showing a turnover rate of 39.86% [3] - Other companies with notable turnover rates included Zhong Sheng Pharmaceutical at 3.92% and Hua Hai Pharmaceutical at 7.28% [3] - The overall market sentiment in the innovative drug sector appears positive, with several stocks experiencing substantial gains and strong capital inflows [2][3]